Novo Nordisk and telehealth firm Hims & Hers reached an agreement under which Hims will sell Novo’s GLP‑1 obesity and diabetes medicines on its platform and curb promotion of compounded alternatives. Novo will dismiss its pending patent suit against Hims while reserving the right to refile, and Hims agreed to offer FDA‑approved branded treatments at standard telehealth prices. The deal reverses a high‑profile clash driven by demand for GLP‑1 drugs, compounding controversies, and regulatory scrutiny. Novo said the agreement broadens access through established telehealth channels; Hims will give existing patients an option to transition to approved products. Regulators and payers will monitor whether the pact reduces unsafe compounding practices and how it impacts prescribing volumes and pricing dynamics across digital health distributors.